HBM backs Obseva’s CHF 60m series-B

Besides HBM, new investors also include New Enterprise Associates (NEA), OrbiMed and Rock Springs Capital. Existing investors Sofinnova Partners, Sofinnova Ventures, Novo Ventures and MS Ventures also provided fresh capital.

The round's proceeds will support progress in Obseva's late-stage pipeline of drugs for the treatment of women's reproductive health conditions.

Previous funding
In August 2013, Sofinnova Partners led a CHF 32m series-A round for Obseva. Danish venture house Novo and Sofinnova Ventures provided co-investment.

Sofinnova Partners began working with Obseva at the start of 2013, providing seed capital to the firm, with co-investment from Loumaye.

Company
Founded in 2012 and based in Geneva, Obseva is a biopharmaceutical company focused on women's reproductive medicine. Its main focus is on the development of therapies for premature labour.

People
Rafaèle Tordjman is managing partner at Sofinnova Partners. In conjunction with the financing, NEA partner Ed Mather will join Obseva's board of directors.

Advisers
Company – Leerink Partners (Corporate finance).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Healthcare
• Early-stage
• DACH
• Switzerland
• Venture